NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm Before September 30th

Core Viewpoint - A class action lawsuit has been filed against Novo Nordisk A/S for allegedly providing misleading statements regarding its growth potential and market performance during the class period from May 7, 2025, to July 28, 2025 [8]. Allegation Details - The lawsuit claims that Novo made overly positive statements while concealing material adverse facts about its growth potential, particularly regarding the compounded GLP-1 market and the likelihood of patients switching to Novo's branded alternatives [8]. - The complaint highlights that Novo's assertions about its market potential were significantly overstated, leading to investor losses when the company later lowered its sales and profit outlook [8]. Market Impact - Following Novo's announcement on July 29, 2025, regarding lowered growth expectations for its products Wegovy and Ozempic, the company's stock price fell from $69.00 to $53.94 per share, representing a decline of approximately 21.83% in one day [8]. Next Steps - Investors who purchased Novo shares during the class period and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is September 30, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].